News

Arrowhead Pharmaceuticals sought approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a…
Read More...

Clinical-stage biotechnology company, Aravive Biologics, Inc aiming to focus on development of treatments for Cancer and fibrotic diseases declared the commencement of  Phase 1 clinical…
Read More...

Arrowhead Pharmaceuticals seeks FDA's orphan drug designation to ARO-AAT.  Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease…
Read More...

Banyan Biomarkers asserted that the U.S FDA has extended De Novo request for the commercialization of Banyan BTI Brain Trauma Indicator), an in vitro diagnostic blood test to aid in the…
Read More...

Celgene Corporation asserted that data from a randomized, placebo-controlled, multi-center, phase II clinical trial of apremilast in patients with active ulcerative colitis who had…
Read More...

Arterys Inc declared its fifth 510 (k) clearance for Arterys Oncology AI suite and is milestone indicative of the company's momentum in applying AI to further medical imaging accuracy…
Read More...

Applied artificial intelligence healthcare company, Viz.ai asserted that the US FDA has extended a De Novo request for the first-ever Computer -Aided Triage and Notification Platform to…
Read More...

DreaMed Diabetes asserted that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes. DreaMed…
Read More...

Evofem Biosciences aiming to meet women's unmet healthcare needs asserted completion of enrollment in its Phase 3 Clinical Trial evaluating Amphora vaginal gel for the prevention of…
Read More...

Citius Pharmaceuticals emphasizing on adjunctive cancer care and critical care drug products affirmed the enrollment of first patient into the Mino-Lok Phase 3 Clinical Trial for…
Read More...

Eisai declared positive results of Phase 3 study for its discovered and developed anticancer agent lenvatinib mesylate in patients grappling with unresectable hepatocellular carcinoma…
Read More...

Merck KGaA, Darmstadt, Germany, and Pfizer assert results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or…
Read More...

Tusker Medical announced the enrollment of first- in-office patients in the OTTER Study implied for Tusker's  TULA (Tubes Under Local Anesthesia) System. Via an approved Investigational…
Read More...

Intralytix proclaimed having sought Food and Drug Administration's clearance to commence Phase I/IIa Clinical Trials at Mount Sinai hospital in New York. Dating back to July,2015,…
Read More...

Regentys, a regenerative medicine company, announced it will partner with Cook Biotech Inc., collaborate to develop a novel treatment for ulcerative colitis.Cook Biotech will develop…
Read More...

Astellas Pharma has acquired Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human…
Read More...

ImmunoQure will collaborate with Servier to advance ImmunoQure's therapeutic human Interferon-α autoantibody through preclinical development and into the clinic where Servier will be…
Read More...

Spineology is exhilarated to declare that enrollment stands complete in the SCOUT clinical trial. The SCOUT (Spineology Clinical Outcomes Trial) IDE, conducted under an FDA-approved…
Read More...

Glooko declared that the US FDA has conceded its Mobile Insulin Dosing System (MIDS) for the titration of long-acting insulin for people with type 2 diabetes. The system includes…
Read More...

Bristol-Myers Squibb Company and Nektar Therapeutics collaborate commercially for Nektar's lead immuno-oncology program, NKTR-214. The companies will jointly develop and…
Read More...